Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | CCNC | P24863 | 9/20 | 0.45 |
| ▸ | CDK8 | P49336 | 9/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048522 | 0.79 | FGFR3 (0.53) | ERN1GRM2PDK2 | |
| SCHEMBL19154127 | 0.79 | ERN1 (0.53) | ERN1GRM2 | |
| SCHEMBL612984 | 0.75 | BRD4 (0.53) | ERN1CCNCCDK8GRM2PDK2 | |
| SCHEMBL25280252 | 0.74 | ERN1 (0.51) | ERN1CCNCCDK8GRM2 | |
| SCHEMBL368567 | 0.73 | MET (0.56) | — | |
| SCHEMBL12516034 | 0.73 | EPHB4 (0.50) | CCNCCDK8PDK2 | |
| SCHEMBL16278740 | 0.71 | ERN1 (0.48) | ERN1CCNCCDK8GRM2 | |
| SCHEMBL18397077 | 0.71 | PIM1 (0.52) | CCNCCDK8 | |
| SCHEMBL29538946 | 0.71 | PIM1 (0.52) | CCNCCDK8 | |
| SCHEMBL16675749 | 0.71 | PRKCI (0.51) | CDK8PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662204-A2 | TELOMERASE INHIBITOR COMPOUNDS | Geron Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-10-17 | — | — | US | disclosed |
| WO-2024168165-A2 | TELOMERASE INHIBITOR COMPOUNDS | GERON CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | TERT, POT1, TERF2 | ERN1 174/4885CCNC 575/4885CDK8 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.